Alembic lands 180-day exclusivity shot on $91m US cancer drug
Tentative USFDA approval for the generic of Bayer's Vitrakvi makes Alembic the sole first applicant. The US market for the oncology drug is $91 million.
— 4 earlier stories on Alembic Pharmaceuticals Ltd. →What's new
- Alembic got tentative USFDA approval for generic Larotrectinib, a kinase inhibitor for certain solid tumors with NTRK gene fusions.
- The drug is the generic of Bayer's Vitrakvi, with an estimated US market of $91 million.
- Alembic is the sole first-to-file applicant with a Paragraph IV certification, granting 180-day marketing exclusivity upon final approval.
Why this matters
This is Alembic's first major oncology win of scale. The $91 million US market for Larotrectinib is about 10% of Alembic's annual revenue of ₹7,345 cr, making it the most material single-product opportunity in the recent pipeline. The sole Paragraph IV status means no competition for six months once it launches.
What we're watching
- Final USFDA approval timing, which determines when Alembic can launch.
- Competitor ANDA filings that could challenge the 180-day exclusivity window.
- Sales ramp-up and pricing strategy for the oncology launch in the US.
The full read
Alembic Pharmaceuticals landed tentative USFDA approval for a generic version of Bayer's Vitrakvi, a targeted cancer drug. The US market for Larotrectinib capsules is estimated at $91 million, or about 10% of Alembic's annual revenue. Critically, Alembic is the sole first applicant with a Paragraph IV certification, securing a 180-day marketing exclusivity window once final approval is granted. The drug treats solid tumors with NTRK gene fusions. This is Alembic's most material single-product opportunity in the US market to date, far exceeding the scale of recent approvals like generic Haloperidol (a $27M market) or the Synthroid launch. The approval strengthens Alembic's oncology pipeline but remains tentative, meaning launch is not immediate. What changes from here is the timing of final clearance and the execution of the US rollout.
Questions answered
- What is the significance of the Paragraph IV certification?
- A Paragraph IV certification means Alembic challenged Bayer's patent on Vitrakvi. Being the sole first applicant with this certification makes Alembic eligible for 180 days of generic marketing exclusivity in the US, blocking other generics.
- How large is the opportunity for Alembic relative to its size?
- The $91 million US market for Larotrectinib represents over 10% of Alembic's annual revenue of ₹7,345 cr. For a mid-cap pharma, that's a significant single-product catalyst.
- When can Alembic start selling the drug in the US?
- Not yet. Tentative approval means the USFDA has found the application acceptable but it cannot be marketed until patent issues are resolved or the patent expires. Final approval is the trigger for launch.
- How does this approval fit into Alembic's US strategy?
- This is a higher-value oncology product compared to recent generic approvals like Haloperidol (US market of $27M) or Synthroid. It strengthens Alembic's US portfolio with a specialty drug, not just a high-volume generic.
- What is the drug's therapeutic use?
- Larotrectinib is a kinase inhibitor used to treat certain solid tumors that have an NTRK gene fusion. It's a targeted oncology therapy, not a broad-spectrum cancer drug.
Alembic Pharmaceuticals Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on APLLTD →- 11 Jun 2026 · 12:48 PM IST Alembic lands 180-day exclusivity shot on $91m US cancer drug
- 5d ago Alembic takes 45% in new Canadian pharma JV with Difgen Holdings
- 6d ago Alembic lands generic Haldol approval, but the US market is tiny
- 20d ago Alembic lands US launch for generic Synthroid into a $1.87bn market
- 21d ago Alembic sets FY27 revenue growth target at low double digits